Format

Send to

Choose Destination
Am J Cardiovasc Drugs. 2019 Apr;19(2):113-131. doi: 10.1007/s40256-018-0312-1.

Tackling Residual Atherosclerotic Risk in Statin-Treated Adults: Focus on Emerging Drugs.

Author information

1
South Australian Health and Medical Research Institute, SAHMRI North Terrace, Adelaide, SA, 5001, Australia.
2
South Australian Health and Medical Research Institute, SAHMRI North Terrace, Adelaide, SA, 5001, Australia. stephen.nicholls@sahmri.com.
3
University of Adelaide, Adelaide, SA, Australia. stephen.nicholls@sahmri.com.

Abstract

Epidemiological studies and meta-analyses have consistently suggested the importance of lowering low-density lipoprotein cholesterol (LDL-C) to reduce cardiovascular (CV) events. However, these studies and mechanistic studies using intracoronary imaging modalities have reported patients who continue to experience CV events or disease progression despite optimal LDL-C levels on statins. These findings, including statin intolerance, have highlighted the importance of exploring additional potential therapeutic targets to reduce CV risk. Genomic insights have presented a number of additional novel targets in lipid metabolism. In particular, proprotein convertase subtilisin/kexin type 9 inhibitors have rapidly developed and recently demonstrated their beneficial impact on CV outcomes. Triglyceride (TG)-rich lipoproteins have been recently reported as a causal factor of atherosclerotic cardiovascular disease (ASCVD). Indeed, several promising TG-targeting therapies are being tested at various clinical stages. In this review, we present the evidence to support targeting atherogenic lipoproteins to target residual ASCVD risk in statin-treated patients.

PMID:
30565156
DOI:
10.1007/s40256-018-0312-1

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center